Zentalis Pharmaceuticals, Inc. announced that Zentalis has initiated patient dosing in three new combination and monotherapy clinical trials: A Phase 1b combination trial with ZN-c5 and abemaciclib (marketed as Verzenio® by Eli Lilly) in ER+/HER2- advanced breast cancer. A Phase 1 combination dose escalation trial with ZN-c3 and chemotherapy in advanced ovarian cancer and A Phase 1 trial with ZN-d5 in acute myeloid leukemia and Non-Hodgkin’s Lymphoma.